IV Therapy Clinic EBITDA Valuation Multiples: What Buyers Are Paying in 2024
Cash-pay IV hydration clinics trade at 3x–5.5x EBITDA. Here's exactly what moves the needle up or down for buyers and sellers in this fragmented wellness sector.
IV therapy clinics typically sell at 3.0x–5.5x EBITDA in the lower middle market. Valuations hinge on recurring membership revenue, transferable medical director agreements, and regulatory compliance. Clinics generating $500K+ EBITDA with documented clinical protocols, 200+ active members, and multi-location footprints command premium multiples from med spa rollup buyers and SBA-financed entrepreneurs.
IV Therapy Clinic EBITDA Multiple Ranges by Tier
| Business Tier | EBITDA Range | Multiple Range | Notes |
|---|---|---|---|
| Distressed or Single-Location Operator | $150K–$300K | 2.5x–3.0x | Walk-in revenue only, owner serves as medical director, no membership program, limited documentation, and unresolved compliance gaps discount value significantly. |
| Established Single-Location Clinic | $300K–$500K | 3.0x–4.0x | Decent membership base, transferable medical director agreement, 2+ years of clean financials, and stable staff qualify for SBA 7(a) financing at this tier. |
| Growth-Stage Multi-Service Clinic | $500K–$750K | 4.0x–5.0x | 200+ active members, diversified services including NAD+ and peptides, strong Google reputation, and a replaceable medical director attract PE-backed rollup interest. |
| Premium Multi-Location Platform | $750K–$2M+ | 5.0x–5.5x | Two or more locations, proven membership retention above 70%, mobile IV unit, documented SOPs, and physician partnerships support top-of-market strategic pricing. |
What Drives IV Therapy Clinic Multiples
Membership Revenue Quality
High Positive impactActive monthly memberships with documented retention and churn data provide predictable cash flow that buyers pay a premium for, often justifying a full multiple turn higher than walk-in-only clinics.
Medical Director Agreement Transferability
High Positive impactA physician willing to remain post-close under a transferable, state-compliant medical director agreement is a prerequisite for SBA financing and removes the single biggest regulatory risk buyers fear.
Owner Dependency Risk
High Negative impactWhen the owner is the sole medical director or primary clinical staff, buyers discount heavily or require extended earnouts to offset the operational collapse risk following transition.
Regulatory and Compliance Documentation
Moderate Positive impactCurrent state health department permits, documented clinical protocols, nurse licensure files, and compliant compounding pharmacy agreements materially reduce buyer due diligence risk and support higher pricing.
Service Menu Diversification
Moderate Positive impactClinics offering NAD+ infusions, peptide injections, and weight management programs alongside hydration therapy generate higher revenue per visit and attract a broader recurring client base.
Recent Market Trends
PE-backed med spa rollup platforms accelerated IV therapy clinic acquisitions in 2023–2024, compressing deal timelines and pushing premium multiples toward 5.5x for membership-driven operators. Simultaneously, FDA scrutiny of compounded infusion products and tightening state regulations around nurse-only administration have increased buyer due diligence intensity, creating a wider valuation gap between compliant and non-compliant sellers.
Sample IV Therapy Clinic Transactions
Single-location IV therapy clinic in a suburban wellness market with 180 active members, transferable medical director agreement, and two years of CPA-reviewed financials. No prior regulatory issues.
$420K
EBITDA
3.8x
Multiple
$1.6M
Price
Two-location cash-pay hydration clinic with NAD+ and peptide services, 310 active members, 72% monthly retention, and a physician retained post-close. SBA 7(a) financed with 15% seller note.
$680K
EBITDA
4.7x
Multiple
$3.2M
Price
Three-location IV therapy platform with mobile unit, documented SOPs, gym referral partnerships, and 4.9-star Google reputation. Acquired by regional med spa rollup as anchor asset.
$1.1M
EBITDA
5.2x
Multiple
$5.7M
Price
EBITDA Valuation Estimator
Get your IV Therapy Clinic business value range instantly
Industry: IV Therapy Clinic · Multiples based on 3.0x–4.0x (Established Single-Location Clinic)
Powered by Deal Flow OS
dealflow-os.com · Free M&A tools for every stage of the deal
Frequently Asked Questions
What EBITDA multiple should I expect when selling my IV therapy clinic?
Most IV therapy clinics sell at 3.0x–5.5x EBITDA. Clinics with transferable medical director agreements, active membership programs, and multi-location footprints command the highest multiples from strategic and PE buyers.
Do IV therapy clinics qualify for SBA financing?
Yes. IV therapy clinics are SBA 7(a) eligible as cash-pay healthcare businesses. Buyers typically finance 75–90% of the purchase price with SBA loans, often paired with a seller note or earnout covering the balance.
What is the biggest factor that reduces an IV therapy clinic's valuation?
Owner dependency as the sole medical director is the top value killer. Without a replacement physician and a transferable medical director agreement, most buyers will not proceed or will demand deep price discounts.
How long does it take to sell an IV therapy clinic?
Expect 12–18 months from exit planning to close. Sellers who document financials, formalize clinical protocols, and recruit a replacement medical director at least 12 months before listing achieve significantly better outcomes and multiples.
More IV Therapy Clinic Guides
Find IV Therapy Clinic businesses at the right price
DealFlow OS surfaces acquisition targets with seller signals and outreach angles. Free to join.
Start finding deals — freeNo credit card required